menu
    • menu
    [{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dana-Farber Cancer Institute \/ Not Applicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Not Applicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BrainStorm Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Autologous MSC-NTF cells","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Dana Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Dana-Farber Cancer Institute \/ Dana Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hale Family Center for Pancreatic Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dana-Farber Cancer Institute","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Autologous Cytokine Induced Memory-Like NK Cell","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"EpicentRx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cytokine Induced Memory-Like Natural Killer Cell","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Invios","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"INV501","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Effector Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Zotatifin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by Dana-Farber Cancer Institute

    Menu

    Dana-Farber Cancer Institute

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zotatifin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Effector Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            eFFECTOR and Dana-Farber to Evaluate Zotatifin in ER+ Endometrial Cancer

                            Details : The collaboration aims to conduct an investigator-sponsored trial evaluating zotatifin in patients with estrogen receptor-positive endometrial cancer and low-grade serous ovarian cancer.

                            Brand Name : eFT226

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : Zotatifin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Effector Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Invios

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            invIOs and Dana-Farber Cancer Institute Start Collaboration to Study Novel Small Molecule INV501 for Treatment...

                            Details : The collaboration aims to evaluate invIOs’ small molecule INV501 that can selectively enhance anti-tumor immune responses, as a potential treatment for glioblastoma.

                            Brand Name : INV501

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 09, 2023

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Invios

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cytokine Induced Memory-Like Natural Killer Cell,Nogapendekin alfa Inbakicept

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : ImmunityBio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tum...

                            Details : Anktiva™ (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex and which is investigated for advanced Head-and-Neck Cancer Patients.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 10, 2023

                            Lead Product(s) : Cytokine Induced Memory-Like Natural Killer Cell,Nogapendekin alfa Inbakicept

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : ImmunityBio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HSB-1216

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Hillstream BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Dru...

                            Details : Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., to develop anti-MUC1-C antibodies to selectively deliver Hillstream’s Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis.

                            Brand Name : HSB-1216

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 31, 2023

                            Lead Product(s) : HSB-1216

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Hillstream BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : EpicentRx

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EpicentRx Announces Poster Presentation for Phase 2 Randomized Clinical Trial with RRx-001 as an Anti-Mucositi...

                            Details : RRx-001 leads EpicentRx's CyNRGY platform as a first-in-class investigational treatment sourced from an exclusively licensed portfolio of aerospace-derived small molecules.

                            Brand Name : RRx-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : RRx-001,Cisplatin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : EpicentRx

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KP1237,Autologous Cytokine Induced Memory-Like NK Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Biohaven Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molec...

                            Details : BHV-1100 targets the destruction of CD38-expressing cells in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immune globulin (Ig) in multiple myeloma patients undergoing autologous stem cell transplant.

                            Brand Name : BHV-1100

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 27, 2021

                            Lead Product(s) : KP1237,Autologous Cytokine Induced Memory-Like NK Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Biohaven Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirogacestat Hydrobromide,Anti-B-cell Maturation Antigen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : SpringWorks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SpringWorks Therapeutics Enters Into Research Collaboration with Leading Cancer Institute to Evaluate Nirogace...

                            Details : The collaboration is designed to further investigate nirogacestat, SpringWorks’ investigational gamma-secretase inhibitor (GSI), with anti-B-cell maturation antigen (BCMA) agents in a variety of preclinical multiple myeloma models.

                            Brand Name : PF-03084014

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 30, 2021

                            Lead Product(s) : Nirogacestat Hydrobromide,Anti-B-cell Maturation Antigen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : SpringWorks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Hale Family Center for Pancreatic Cancer Research

                            Deal Size : $80.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Dana-Farber Receives $50 million Funding to Study Pancreatic Cancer

                            Details : Funding will enable a wide range of ambitious work in two main areas of pancreatic cancer research: early detection and prevention, and precision medicine and biology.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 11, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Hale Family Center for Pancreatic Cancer Research

                            Deal Size : $80.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous MSC-NTF cells

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : BrainStorm Cell Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BrainStorm Initiates NurOwn Expanded Access Programme for ALS Patients Who Meet Specific Eligibility Criteria

                            Details : Through the newly announced EAP, the six clinical centers of excellence participating in the Phase 3 NurOwn® trial will each have the opportunity to treat ALS patients who completed the trial.

                            Brand Name : NurOwn

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 14, 2020

                            Lead Product(s) : Autologous MSC-NTF cells

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : BrainStorm Cell Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axicabtagene Ciloleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CAR T-Cell Therapy Found Highly Effective in Patients with High-Risk Non-Hodgkin Lymphoma

                            Details : In the current trial, dubbed ZUMA-5, investigators administered axi-cel to 146 patients with follicular lymphoma or marginal zone lymphoma-two slow-growing forms of non-Hodgkin leukemia-at multiple U.S. medical centers.

                            Brand Name : Yescarta

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 05, 2020

                            Lead Product(s) : Axicabtagene Ciloleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth